Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics (HALO) reported stronger quarterly results. For the three months ended September 30, 2025, total revenues were $354,264,000 versus $290,084,000 a year ago, driven by royalties of $236,038,000 and product sales of $94,228,000. Net income was $175,225,000 compared to $137,011,000, with diluted EPS of $1.43 versus $1.05.
For the nine months, revenue reached $944,844,000 versus $717,316,000, and net income was $458,480,000 versus $307,079,000, reflecting broad growth in royalties and milestones. Operating cash flow was $432,529,000, supporting cash and cash equivalents of $419,665,000 at quarter end.
The company repurchased common stock using $342,372,000 year-to-date. On the balance sheet, current portion of long-term debt, net, was $710,685,000 and long-term debt, net, was $800,072,000. Shares outstanding were 117,597,000 as of October 27, 2025. Stockholders’ equity increased to $503,915,000 from $363,821,000 at December 31, 2024.
Halozyme Therapeutics, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 under Item 2.02.
The company also disclosed a planned CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue as CFO until the earlier of when a new CFO is hired or March 30, 2026, after which she will depart to pursue a new professional opportunity. Halozyme has initiated a search for its next CFO.
The company stated that Ms. LaBrosse’s departure is not due to any disagreement with its independent auditors or with the company regarding financial statements, internal control over financial reporting, operations, policies, or practices. The company expects to enter into a transition and release agreement with Ms. LaBrosse.
Halozyme Therapeutics (HALO) furnished a Regulation FD update announcing it issued a statement on the final IPAY 2028 guidance for Medicare price negotiations from the U.S. Centers for Medicare & Medicaid Services. The statement includes the company’s long‑term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE partner product subcutaneous sales. The statement is available on the company’s website and attached as Exhibit 99.1. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference.
Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of $68.98 and was granted 3,625 restricted stock units (RSUs). The option vests 25% on 10/03/2026 then monthly thereafter over the remaining term to 10/03/2035. The RSU award vests 25% on the first anniversary and then in annual 25% installments thereafter. Following these transactions, the reporting person beneficially owns 9,031 option-derived shares and 3,625 RSUs, reported as direct ownership.
HALO officer Cortney Caudill filed an initial Form 3 reporting direct ownership of 7,674 shares and equity awards that can convert to common stock. The reported awards include stock options exercisable for 89,224 and 11,302 shares with exercise prices of $33.51 and $57.44, restricted stock units totaling 38,641 shares, and performance stock units totaling 11,483 shares. Altogether these positions represent approximately 150,650 underlying shares subject to vesting and exercise schedules tied to service and performance.
Halozyme Therapeutics, Inc. reported a leadership change, appointing Cortney Caudill as Senior Vice President, Chief Operating Officer effective October 1, 2025. She previously served as the company’s Senior Vice President, Chief Operations Officer since October 2023 and has more than two decades of operational experience at multiple life sciences companies, including Aeglea Biotherapeutics and several global biotechnology and pharmaceutical organizations.
Ms. Caudill will receive an initial annual base salary of $600,000 and has a 2025 bonus target equal to 50% of her base salary under the company’s executive incentive plans. In connection with her appointment, she will receive an equity award valued at $500,000, split equally between stock options and restricted stock units, which will vest over four years under Halozyme’s standard vesting schedule. The company states there are no family relationships or related-party transactions involving Ms. Caudill in her new role.
Halozyme Therapeutics entered into an Agreement and Plan of Merger to combine with Elektrofi, Inc. under which Halozyme's wholly owned subsidiary Erraid Merger Sub Inc. will merge into Elektrofi and Elektrofi will survive as a wholly owned subsidiary of Halozyme. The filing names Shareholder Representative Services LLC as the securityholders' representative. The disclosure describes the planned corporate combination but does not disclose financial terms, timing, or regulatory approvals in the provided excerpt.
Halozyme Therapeutics (HALO) Form 144 notice reports a proposed sale of 136,569 shares of common stock through J.P. Morgan Securities, with an aggregate market value reported as $10,015,970 and an approximate sale date of 10/01/2025 on NASDAQ. The filing shows the shares were acquired on 10/01/2025 via stock option exercise and paid in cash. Recent disclosed sales by the same person, Helen Torley, list nine separate transactions from 07/08/2025 through 09/04/2025, each of 20,000 shares, with gross proceeds shown for each trade.
Halozyme Therapeutics reported that it executed an Agreement and Plan of Merger with Elektrofi, Inc., with the combination to be implemented through Erraid Merger Sub Inc.
The merger agreement is dated September 30, 2025 and names Shareholder Representative Services LLC as shareholder representative. Halozyme issued a press release on October 1, 2025 describing this transaction, which is furnished as Exhibit 99.1 to this report.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.